stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
18.23
1.06
−5.50%
Follow MMED
Alert me
| Apr '24 | Apr '25 | Apr '26 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 2.53 |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 4.28 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (3.09) |
P/Operating CF |
(173.13) | (173.13) | (115.55) |
P/B ratio |
1.35 | 1.35 | 0.86 |
Price to Tangible BV |
4.27 | 4.27 | 2.50 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(166.59) | (166.59) | (100.78) |
EV/FCF |
(10.58) | (10.58) | (6.40) |
Quick Ratio |
— | 0.82 | 0.71 |
Current Ratio |
— | 1.32 | 1.92 |
Net Debt/EBITDA |
0.00 | 5.50 | 8.76 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 1.29 | 0.70 |
Operating CF/Net income |
(0.37) | (0.66) | 0.59 |
Capex/Depreciation |
(1.15) | (1.35) | (1.43) |
| 0.00% | 0.00% | (9.59%) | |
| 0.00% | (10.14%) | (7.54%) | |
ROIC |
0.00% | (2.73%) | (3.58%) |
Return on Tangible Assets |
0.00% | (22.78%) | (24.54%) |
Average Days of Receivables |
0.00 | 76.63 | 23.53 |
Research and Development Expense of Revenue |
17.70% | 16.06% | 14.44% |
Selling, General and Administrative Expense of Revenue |
42.81% | 39.78% | 38.14% |
Intangible Assets out of Total Assets |
0.00 | 0.57 | 0.51 |
Share Based Compensation of Revenue |
1.54% | 1.51% | 1.48% |
Graham Net Nets |
0.05 | 0.05 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(3.27%) | (3.27%) | (3.27%) |
Free Cash Flow Yield |
(9.43%) | (9.43%) | (14.14%) |
Revenue per Share |
9.77 | 10.74 | 12.09 |
Operating CF per Share |
0.16 | 0.55 | (0.77) |
Capex per Share |
(0.59) | (0.76) | (0.87) |
Free Cash Flow per Share |
(0.42) | (0.21) | (1.64) |
Cash per Share |
0.00 | 0.04 | 1.16 |
Shareholders Equity per Share |
0.00 | 13.17 | 14.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 13.17 | 14.07 |
Free Cash Flow |
(107.00) | (53.00) | (420.00) |
Working Capital |
— | 229.00 | 646.00 |
Capital Expenditures |
(148.00) | (193.00) | (223.00) |
Net Current Asset Value |
0.00 | 68.00 | 329.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.07 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 0.20 | 0.22 |
Cash ROIC |
0.00% | (1.59%) | (10.74%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.06 |
Accounts Payable Turnover |
0.00 | 0.00 | 7.73 |
Inventory Turnover |
0.00 | 0.00 | 4.36 |
Average Days of Payables |
0.00 | 63.04 | 41.84 |
Days of Inventory on Hand |
0.00 | 95.63 | 87.53 |
Average Receivables |
— | — | 385.00 |
Average Payables |
— | — | 184.00 |
Average Inventory |
— | — | 326.00 |
Average Assets |
— | 2,100.50 | 4,415.50 |
Average Common Equity |
— | — | 3,471.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026